Latest Conference Articles

A real-world study found just one-third of patients remained on adjuvant osimertinib at 3 years, with early discontinuation linked to worse disease-free survival.

Primary results from the phase 3 ARTEMIS-008 trial presented at WCLC 2026 showed risvutatug rezetecan reduced the risk of death by 54% and more than doubled PFS.

Tambotatug pelitecan improved survival and confirmed ORR in the phase 3 TAISHAN-302 trial presented at WCLC 2026.

Stephen V. Liu, MD, discusses building on durvalumab consolidation with tarlatamab and other novel agents in limited-stage SCLC.

Enriqueta Felip, MD, PhD, discusses selecting next-generation ROS1 TKIs after progression on crizotinib or entrectinib in NSCLC.

Luis Paz-Ares, MD, PhD, discusses protocols for managing T-cell engager and antibody-drug conjugate toxicities in lung cancer.

Randomized dose-expansion data from the global phase 1 study establish the recommended phase 3 dose for the EGFR x HER3 bispecific ADC in the IZABRIGHT-Lung01 trial.

Tetsuya Mitsudomi, MD, PhD, discusses classifying and individualizing treatment for uncommon EGFR mutations in NSCLC.

Yang Xia, MD, PhD, discusses strategies for overcoming EGFR TKI resistance, including biomarker-selected and -unselected approaches.

Final analysis of the phase 3 IMpower030 trial showed a median EFS of 62.8 months versus 34.9 months with placebo plus chemotherapy in stage IIB to IIIB disease.

Molly Li, MBBS, discusses selecting between HER2-directed TKIs and antibody-drug conjugates in first-line HER2-mutant NSCLC.

First data from the phase 1B/2 BNT324-01 trial pair a PD-L1 and VEGF-A bispecific antibody with a B7H3-directed ADC in patients with SCLC.

Every-3-week and every-4-week tarlatamab regimens produced ORRs of 31% and 27% vs 40% with standard bi-weekly dosing in the phase 2 DeLLphi-309 trial.

The dose-finding DeLLphi-308 trial showed promising results for a more convenient administration of tarlatamab in patients with ES-SCLC.

The phase 3 LONESTAR trial was closed early for futility after added local consolidative therapy showed no OS or PFS benefit, including in oligometastatic disease.

Grant outlines open questions in perioperative NSCLC, from neoadjuvant sequencing and adjuvant selection to whether ctDNA is ready for practice.

A hematology-oncology fellow explains how trainees can use poster walks, follow-up contact, and review articles to find mentors and generate research questions.

The ASC4FIRST trial continued to show higher molecular response rates and better tolerability with asciminib than with standard TKIs in Ph-positive CML.

Prophylactic tocilizumab before step-up dosing lowered CRS rates approximately 5-fold with teclistamab and talquetamab in relapsed/refractory myeloma.

Rusfertide preserved efficacy and safety benefits over placebo in both low- and high-risk polycythemia vera.

Prithviraj Bose, MD, discusses selinexor's existing myeloma approval and how phase 3 SENTRY data could shape its use with ruxolitinib in myelofibrosis.

Naseema Gangat, MBBS, reviews cohort-specific hematologic response rates and safety findings for selcodebart in myelofibrosis.

In the PIVOT-CLL trial, time-limited pirtobrutinib, venetoclax, and obinutuzumab produced deep, durable molecular remissions in treatment-naive CLL.

A prespecified analysis showed benefit with anselamimab in patients with kappa light chain AL amyloidosis.

David Sallman, MD, discusses planned development and combination strategies for the NEK7 inhibitor ofirnoflast in lower-risk MDS.

Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.

Revumenib added to intensive chemotherapy produced deep, MRD-negative remissions with a manageable safety profile in newly diagnosed AML.

Naseema Gangat, MBBS, discusses phase 2 efficacy and safety data for DISC-3405, an anti-TMPRSS6 monoclonal antibody, in polycythemia vera.

Ofirnoflast produced hematologic improvement in two-thirds of patients with ESA-refractory lower-risk MDS.

In the phase 2 RESTORE-PV trial, DISC-3405 cut phlebotomy events and maintained hematocrit below 45% in patients with polycythemia vera.